221 related articles for article (PubMed ID: 24698326)
1. Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase δ syndrome.
Kracker S; Curtis J; Ibrahim MA; Sediva A; Salisbury J; Campr V; Debré M; Edgar JD; Imai K; Picard C; Casanova JL; Fischer A; Nejentsev S; Durandy A
J Allergy Clin Immunol; 2014 Jul; 134(1):233-6. PubMed ID: 24698326
[No Abstract] [Full Text] [Related]
2. Activated PI3-kinase δ Syndrome: Long-term Follow-up after Cord Blood Transplantation.
Ceraulo A; Malcus C; Durandy A; Picard C; Bertrand Y
J Clin Immunol; 2016 Aug; 36(6):544-6. PubMed ID: 27294376
[No Abstract] [Full Text] [Related]
3. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM; Chandra A
Front Immunol; 2018; 9():338. PubMed ID: 29556229
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of an activated PI3K-δ syndrome 2 in patient presenting with an agammaglobulinemia phenotype.
Nguyen Y; Rosain J; Aguilar C; Picard C; Malphettes M
Ann Allergy Asthma Immunol; 2018 Dec; 121(6):739-740.e1. PubMed ID: 30081089
[No Abstract] [Full Text] [Related]
5. Report of a Chinese Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome.
Wang Y; Wang W; Liu L; Hou J; Ying W; Hui X; Zhou Q; Liu D; Yao H; Sun J; Wang X
J Clin Immunol; 2018 Nov; 38(8):854-863. PubMed ID: 30499059
[TBL] [Abstract][Full Text] [Related]
6. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation.
van Zelm MC; Bartol SJ; Driessen GJ; Mascart F; Reisli I; Franco JL; Wolska-Kusnierz B; Kanegane H; Boon L; van Dongen JJ; van der Burg M
J Allergy Clin Immunol; 2014 Jul; 134(1):135-44. PubMed ID: 24418477
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
8. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
9. In vivo but not in vitro stimulations rescue of the defective class switching to IgG or IgA in B-cells of immunodeficiency with hyper IgM.
Saiki O; Uda H; Hayashi M; Tanaka T; Katada Y; Shimizu M; Kinoshita N; Kishimoto T
Clin Immunol Immunopathol; 1997 Jun; 83(3):287-92. PubMed ID: 9175918
[TBL] [Abstract][Full Text] [Related]
10. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
11. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
12. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage.
Angulo I; Vadas O; Garçon F; Banham-Hall E; Plagnol V; Leahy TR; Baxendale H; Coulter T; Curtis J; Wu C; Blake-Palmer K; Perisic O; Smyth D; Maes M; Fiddler C; Juss J; Cilliers D; Markelj G; Chandra A; Farmer G; Kielkowska A; Clark J; Kracker S; Debré M; Picard C; Pellier I; Jabado N; Morris JA; Barcenas-Morales G; Fischer A; Stephens L; Hawkins P; Barrett JC; Abinun M; Clatworthy M; Durandy A; Doffinger R; Chilvers ER; Cant AJ; Kumararatne D; Okkenhaug K; Williams RL; Condliffe A; Nejentsev S
Science; 2013 Nov; 342(6160):866-71. PubMed ID: 24136356
[TBL] [Abstract][Full Text] [Related]
13. Exhaustion of the CD8
Wentink MWJ; Mueller YM; Dalm VASH; Driessen GJ; van Hagen PM; van Montfrans JM; van der Burg M; Katsikis PD
Front Immunol; 2018; 9():446. PubMed ID: 29563914
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel de novo gain-of-function mutation of PIK3CD in a patient with activated phosphoinositide 3-kinase δ syndrome.
Luo Y; Xia Y; Wang W; Li Z; Jin Y; Gong Y; He T; Li Q; Li C; Yang J
Clin Immunol; 2018 Dec; 197():60-67. PubMed ID: 30138677
[TBL] [Abstract][Full Text] [Related]
15. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
16. Successful bone marrow transplantation in two sisters with activated phosphoinositide 3-kinase δ syndrome 2.
Sugiyama M; Iguchi A; Yamada M; Terashita Y; Ohshima J; Cho Y; Miyake N; Matsumoto N; Ueki M; Yamazaki Y; Takezaki S; Kobayashi I; Ariga T
Bone Marrow Transplant; 2017 Dec; 52(12):1678-1680. PubMed ID: 28869616
[No Abstract] [Full Text] [Related]
17. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
[TBL] [Abstract][Full Text] [Related]
18. A novel germline gain-of-function variant in PIK3CD.
Rae W; Gao Y; Ward D; Mattocks CJ; Eren E; Williams AP
Clin Immunol; 2017 Aug; 181():29-31. PubMed ID: 28578023
[No Abstract] [Full Text] [Related]
19. Hyper-activated PI3K-δ in immunodeficiency.
Heurtier L; Deau MC; Kracker S
Oncotarget; 2015 Jul; 6(21):18242-3. PubMed ID: 26286043
[No Abstract] [Full Text] [Related]
20. Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.
Nemoto M; Hattori H; Maeda N; Akita N; Muramatsu H; Moritani S; Kawasaki T; Maejima M; Ode H; Hachiya A; Sugiura W; Yokomaku Y; Horibe K; Iwatani Y
Sci Rep; 2018 May; 8(1):6956. PubMed ID: 29725107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
